Generic Name and Formulations:
Mesalamine 1.2g; del-rel tabs.
Shire US, Inc.
Indications for LIALDA:
To induce remission in active, mild-to-moderate ulcerative colitis; and to maintain remission of ulcerative colitis.
≥18yrs: Swallow whole with a meal. 2.4–4.8g once daily for up to 8 weeks. Maintenance: 2.4g once daily.
<18yrs: not established.
Sulfasalazine allergy. Upper GI tract obstruction (eg, pyloric stenosis) may delay onset of action. Discontinue if acute intolerance syndrome is suspected. Conditions predisposing to myocarditis or pericarditis. Atopic dermatitis or eczema: may have more severe photosensitivity reactions. Renal or hepatic impairment. Monitor renal function prior to and periodically during therapy. Elderly (monitor CBCs). Pregnancy (Cat.B). Nursing mothers.
Increased toxicity with nephrotoxic drugs (eg, NSAIDs). Increased risk of blood disorders with azathioprine or 6-mercaptopurine. May cause elevated test results in measuring urinary normetanephrine.
Ulcerative colitis, headache, flatulence, abnormal LFTs, abdominal pain; acute intolerance syndrome (cramping, bloody diarrhea, fever, headache, rash), renal impairment, cardiac hypersensitivity reactions, pancreatitis (rare).
Endocrinology Advisor Articles
- Relationship Between HbA1c and Coronary Artery Disease
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- FDA to Review Gimoti for Diabetic Gastroparesis in Adult Women
- FDA Approves First Mobile App for Use in Preventing Pregnancy
- Hypothyroidism Predicts Atrial Tachyarrhythmia After AF Catheter Ablation
- Treating Painful Diabetic Peripheral Neuropathy With Electroacupuncture